What is the difference between a 361 HCT/P and a 351 biologic, and why does it matter to a clinic owner?
Short answer
Both names come from sections of the Public Health Service Act. A 361 HCT/P meets all of the criteria in 21 CFR 1271.10(a) and is regulated under 21 CFR Part 1271 without premarket review, while a 351 biological product needs a biologics license in effect before it is introduced into interstate commerce. For a clinic owner, the category decides whether a product can lawfully be marketed without premarket review as a drug, device or biological product, and that shapes what anyone can say about it.
Where the two numbers come from
"361" and "351" are section numbers in the Public Health Service Act (PHS Act). Section 361 appears in the US Code at 42 U.S.C. 264, which authorizes regulations to stop communicable diseases from being introduced, transmitted or spread. Section 351 appears at 42 U.S.C. 262, which requires a biologics license before a biological product is introduced into interstate commerce.
FDA's rules for human cells, tissues and cellular and tissue based products (HCT/Ps) are in 21 CFR Part 1271. FDA's guidance on minimal manipulation and homologous use describes them as a tiered, risk based approach: HCT/Ps that meet specific criteria or fall within detailed exceptions do not require premarket review and approval, and others do.
Side by side
| 361 HCT/P | 351 biological product | |
|---|---|---|
| Basis in law | Section 361 of the PHS Act and 21 CFR Part 1271, when every criterion in 21 CFR 1271.10(a) is met | Section 351 of the PHS Act and/or the Federal Food, Drug, and Cosmetic Act, as 21 CFR 1271.20 sets out for HCT/Ps that miss a criterion |
| Premarket review | Not required, per FDA's guidance | A biologics license must be in effect (42 U.S.C. 262(a)); use in clinical studies before that needs an investigational new drug application in effect, per FDA's guidance |
| FDA review before marketing | None required. FDA accepts the establishment's registration and listing, and that acceptance is not a determination of compliance, licensure or approval (21 CFR 1271.27(b)) | FDA's guidance says licenses are issued only after FDA determines that the establishment and the product meet the requirements meant to ensure the product's continued safety, purity and potency |
| Registration | The establishment registers and lists under Part 1271 (21 CFR 1271.10(b)) | The establishment registers and lists under 21 CFR part 207 or 807 (21 CFR 1271.1(b)(2)) |
| Donor eligibility (subpart C) and current good tissue practice (subpart D) procedures in Part 1271 | Apply | Also apply, per 21 CFR 1271.1(b)(2) |
| How it is described | Intended use, as shown by labeling, advertising and other indications of the manufacturer's objective intent, must be homologous use only (21 CFR 1271.10(a)(2)) | A product that requires but lacks premarket approval may not be lawfully marketed, per FDA's questions and answers on the end of its enforcement policy |
How a product ends up in one or the other
The test is in 21 CFR 1271.10(a): minimal manipulation, homologous use only, no combination with another article beyond narrow exceptions, and a condition on systemic effect and metabolic activity. The criteria are explained in What are the FDA 361 HCT/P criteria and what do they mean for clinics?
If an HCT/P misses any one criterion and its manufacturer qualifies for no exception in 21 CFR 1271.15, 21 CFR 1271.20 says it is regulated as a drug, device, and/or biological product. Because homologous use depends on intended use, FDA's guidance gives examples where the same kind of HCT/P is a homologous use for one intended use and not for another. That means the category belongs to a specific product with a specific intended use, not to a kind of tissue.
FDA's guidance also describes how a manufacturer can get FDA's view on a specific HCT/P: an informal recommendation from the Tissue Reference Group, or a formal decision through a Request for Designation.
Where marketing labels fit
"Stem cell therapy" is not a regulatory category: it is not another name for a 361 HCT/P or for a 351 biological product. Part 1271 does not define it. FDA's consumer pages do address it:
"Stem cell products are regulated by FDA, and, generally, all stem cell products require FDA approval." FDA consumer alert on regenerative medicine products, July 22, 2020
FDA's consumer page on regenerative medicine therapies says there continues to be broad marketing of unapproved products considered regenerative medicine therapies, and that such products require FDA licensure or approval to be marketed to consumers. FDA keeps a public list of approved cellular and gene therapy products, which it describes as licensed products from its Office of Therapeutic Products.
What a clinic owner should ask a supplier
- Is the product described as a 361 HCT/P or as a licensed 351 product? Get the answer in writing.
- If 361: the manufacturer's written basis for each of the four criteria in 21 CFR 1271.10(a), for the product's labeled use, and whether FDA's Tissue Reference Group or a Request for Designation has addressed it.
- If 351: the product's licensed status, which you can compare with FDA's list of approved cellular and gene therapy products.
- The manufacturing establishment's registration, which you can look up in FDA's HCTERS public query. That page says registration and listing is not a determination that an HCT/P is appropriately regulated solely under section 361.
- The labeling and stated uses, so your own patient wording stays within them. See how to market regenerative services compliantly.
Review the answers with a healthcare attorney before you use or describe the product.
Sources
- 42 U.S.C. 262 (PHS Act section 351), United States Code 2024 edition on govinfo, read on 2026-11-20.
- 42 U.S.C. 264 (PHS Act section 361), United States Code 2024 edition on govinfo, read on 2026-11-20.
- 21 CFR Part 1271, including 1271.1, 1271.10, 1271.15, 1271.20 and 1271.27, eCFR, read on 2026-11-20.
- FDA guidance: Regulatory Considerations for HCT/Ps: Minimal Manipulation and Homologous Use, July 2020 (full text), read on 2026-11-20.
- FDA: Questions and Answers Regarding the End of the Compliance and Enforcement Policy for Certain HCT/Ps, read on 2026-11-20.
- FDA consumer alert on regenerative medicine products, dated July 22, 2020, content current as of 2024-04-09, read on 2026-11-20.
- FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies, content current as of 2024-04-08, read on 2026-11-20.
- FDA: list of approved cellular and gene therapy products, content current as of 2026-10-30, read on 2026-11-20.
- FDA: HCTERS Public Query Application, read on 2026-11-20.
Frequently asked questions
Does a 361 HCT/P go through premarket review by FDA?
No. FDA's guidance explains that HCT/Ps meeting all of the criteria in 21 CFR 1271.10(a) do not require premarket review and approval. The establishment that makes them must still register with FDA, list each HCT/P and comply with the rest of 21 CFR Part 1271, under 21 CFR 1271.10(b).
Does a 351 product need a license before it is marketed?
Yes. Under 42 U.S.C. 262(a), which is section 351 of the Public Health Service Act, a biological product may not be introduced into interstate commerce unless a biologics license is in effect for it. FDA's guidance says HCT/Ps regulated as biological products require premarket approval, and that clinical studies before approval need an investigational new drug application in effect.
Can the same kind of tissue be 361 in one use and 351 in another?
It can, according to FDA's guidance on minimal manipulation and homologous use, which gives examples where the same kind of HCT/P is a homologous use for one intended use and not for another. An HCT/P that is not intended for homologous use only does not meet 21 CFR 1271.10(a)(2), so 21 CFR 1271.20 applies unless an exception in 21 CFR 1271.15 does.
Is "stem cell therapy" the same thing as a 361 HCT/P?
"Stem cell therapy" is not a regulatory category: it is not another name for a 361 HCT/P or for a 351 biological product. FDA's consumer alert says that, generally, all stem cell products require FDA approval. Whether any product is regulated solely under section 361 depends on whether it meets every criterion in 21 CFR 1271.10(a).
How can a clinic check a supplier's claim about a product's status?
Look up the manufacturing establishment in FDA's HCTERS public query, keeping in mind that registration is not a determination of status. Check FDA's list of approved cellular and gene therapy products for any product described as licensed. Ask the supplier for the manufacturer's written basis for each criterion in 21 CFR 1271.10(a), and review it with a healthcare attorney.